HLA-C and neoplasm: Our work indicates that loss of both MHC-I and MHC-II pathways often co-occurs in immune checkpoint inhibitor resistance, although we hypothesize that the relative contribution of each MHC molecule will reflect the profile of antigens expressed by the tumor cells.